In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
INmune Bio Inc (NASDAQ: INMB) closed the day trading at $5.33 down -15.13% from the previous closing price of $6.28. In other words, the price has decreased by -$15.13 from its previous closing price. On the day, 59.23 million shares were traded. INMB stock price reached its highest trading level at $11.64 during the session, while it also had its lowest trading level at $5.01.
Ratios:
For a better understanding of INMB, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.64 and its Current Ratio is at 2.64. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Rodman & Renshaw on January 28, 2025, initiated with a Buy rating and assigned the stock a target price of $23.
On October 21, 2024, Alliance Global Partners started tracking the stock assigning a Buy rating and target price of $20.
On September 27, 2024, Raymond James started tracking the stock assigning a Outperform rating and target price of $18.Raymond James initiated its Outperform rating on September 27, 2024, with a $18 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 30 ’24 when Moss David J bought 10,000 shares for $5.29 per share. The transaction valued at 52,868 led to the insider holds 1,285,869 shares of the business.
Tesi Raymond Joseph bought 15,380 shares of INMB for $98,048 on Sep 12 ’24. The President and CEO now owns 1,554,106 shares after completing the transaction at $6.38 per share. On Sep 12 ’24, another insider, Moss David J, who serves as the Chief Financial Officer of the company, bought 7,690 shares for $6.38 each. As a result, the insider paid 49,024 and bolstered with 1,275,869 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, INMB now has a Market Capitalization of 124614336 and an Enterprise Value of 104721312. For the stock, the TTM Price-to-Sale (P/S) ratio is 2474.20 while its Price-to-Book (P/B) ratio in mrq is 4.12. Its current Enterprise Value per Revenue stands at 2094.426.
Stock Price History:
The Beta on a monthly basis for INMB is 1.52, which has changed by -0.36698335 over the last 52 weeks, in comparison to a change of 0.12748289 over the same period for the S&P500. Over the past 52 weeks, INMB has reached a high of $10.50, while it has fallen to a 52-week low of $4.32. The 50-Day Moving Average of the stock is -28.18%, while the 200-Day Moving Average is calculated to be -20.70%.
Shares Statistics:
Over the past 3-months, INMB traded about 522.61K shares per day on average, while over the past 10 days, INMB traded about 7463410 shares per day. A total of 22.93M shares are outstanding, with a floating share count of 16.50M. Insiders hold about 28.90% of the company’s shares, while institutions hold 25.53% stake in the company. Shares short for INMB as of 1749772800 were 7256955 with a Short Ratio of 13.89, compared to 1747267200 on 5870122. Therefore, it implies a Short% of Shares Outstanding of 7256955 and a Short% of Float of 38.48.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The dynamic stock of INmune Bio Inc (INMB) is currently being evaluated by a team of 5.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.41, with high estimates of -$0.34 and low estimates of -$0.49.
Analysts are recommending an EPS of between -$1.49 and -$1.98 for the fiscal current year, implying an average EPS of -$1.71. EPS for the following year is -$1.6, with 5.0 analysts recommending between -$1.11 and -$2.2.
